Index

Access Copyright 202, 214, 220
access to government information 242–4, 265
access to medicines 100–101, 103, 296
Africa 64, 100
Agriculture and Agri-Food Canada, Department of (AAFC) 47–8
animals, transgenic see lifeforms under patents
Apotex 82
appellations of origin 36, 39, 40–42
Argentina 44
ArtistI 201
Audio-Video Licensing Agency (AVLA) 203
Australia copyright collective management 215
geographical indications 37, 40, 52
moral rights 163, 175, 195–6
attribution, right of 187, 188
consent 193, 194
copyright and 176
death of author 195
false attribution 190
indirect infringement 190
integrity, right of 181, 183, 184–5, 186
legislation 179–80
protection period 194
pharmaceutical products 88, 92
Bale Jr., H.E. 83
Barnes, J.J. 130
Bently, L. 268
Bereskin, D.R. 6
Berne Convention 108, 137, 307
moral rights 163, 169, 170, 171, 178, 180–81, 183, 184, 191, 300, 307
bijuralism see civil law; common law bilingualism 309
case reporting 19–21
moral rights 178–9, 180, 182–3, 188, 189–90
trademarks 27
biomedicines 100, 102–3
biotechnology see lifeforms under patents
British Columbia 87, 249–50
Brunet, C. 168, 178
business names 5, 13–14
geographical indications and 44
Canada–European Community Wine and Spirits Agreement 45, 50–53,
64–5, 66, 307
Canadian Artists Representation Copyright Collective (CARCC) 203
Canadian Broadcasters Rights Agency (CBRA) 204, 205
Canadian Musical Reproduction Rights Agency (CMRRA) 202, 207, 214,
215
Canadian Patent Reporter (C.P.R.) 20–21
Canadian Private Copying Collective (CPCC) 207, 214
Canadian Recording Industry Association (CRIA) 228–30
Canadian Screenwriters Collection Society (CSCS) 204
Canadian Whisky 35, 48
Carrière, L. 183–4, 192
case reporting, bilingual 19–21
census 248
certification marks 36, 46, 53–7, 65
Champagne 35, 37, 50, 51, 60
China 101
Chrétien, J. 100
civil law 3, 15, 296, 297–8, 302
Civil Code of Québec 45
art. 1457 15–16, 18, 19, 57–8
Ysolde Gendreau - 9781848445024
Downloaded from Elgar Online at 12/30/2018 12:02:55AM
to via free access
Index

copyright 116, 121, 162, 238, 298–9, 300–301
geographical indications 57–8
harmonization 21
    language, role of 19–21
    passing off 15–19, 20–21
moral rights 172, 175, 176, 178–9, 191, 196, 298
privacy 251–2
trademarks 4–7, 297
CMRRA (Canadian Musical Reproduction Rights Agency) 202, 207, 214, 215
co-existing IP rights see overlapping IP rights
Collective Management Organizations (CMOs) 198, 208–9, 228
see also Copyright Board of Canada 222–3
definition of collective society 199
divergent points of view 214–15
extended repertoire/licensing 220
four legal regimes 199–200
general regime 201–5
music performing rights 200–201
particular cases regime 205–6
private copying 206–7
organization of 212
strategic alliances 214
colonial copyright
Canadian problem 124–6
    embargo on reproduction right 134–7
    importation 126–34
origins of Canadian law
    early case law 121–4
    emergence of copyright doctrine 115–21
    first colonial statutes 110–15
commercialisation trompeuse 16
common law 3, 15, 297–9, 302
copyright 116, 121, 162, 238, 298–9, 300
gatekeepers 57–8
harmonization 21
    language, role of 19–21
    passing off 15–19, 20–21
moral rights 170, 172, 175, 176, 178–9, 196
privacy 248–50, 252
titles of literary works
    passing off 284–6
trademarks 4–7, 30, 33, 297
comparative law, resort to 300–303
competition 289–90, 291, 294, 308–9
    Competition, Commissioner of 204–5
confidential information 16, 252–8
trade secrets 12, 100, 253–4
converging IP rights see overlapping IP rights
COPIBEC (Société québécoise de gestion collective des droits de reproduction) 202, 214
copyright 298
civil law influence 116, 121, 162, 238, 298–9, 300–301
colonial see colonial copyright
economic rights 238–41, 253, 264
    federal powers 4, 8, 11, 12, 113, 296
insubstantial portions of works 238
intellectual property 237–41
moral rights and 176, 239–40, 264
originality standard 139–40
CCH 140–43, 154–61
University of London Press 143–51
Walter v. Lane 151–4
overlapping IP rights 267–70, 308
industrial design 270–73
normative principles 289–93
patent 273–7
    trademark 283–9
    patents and 158, 273–7
public participation 253
users’ rights 239–40, 253, 264
see also moral rights; personal data protection and confidentiality
Copyright Board of Canada 304–5, 306
    administration 210
    advantages of system 215–18
    disadvantages of system 218–19
    establishment of 207–9
    four legal regimes 199–200
    general regime 201–5
    music performing rights 200–201
    particular cases regime 205–6
    private copying 206–7, 305
    future growth 219–21

Ysolde Gendreau - 9781848445024
Downloaded from Elgar Online at 12/30/2018 12:02:55AM
via free access
interaction among CMOs and 214–15
powers of 211–14
procedures before 210–11
CPCC (Canadian Private Copying Collective) 207, 214
CRIA (Canadian Recording Industry Association) 228–30
criminal law/context 246, 248, 253, 264, 266, 276–7
CSCS (Canadian Screenwriters Collection Society) 204

data protection
personal see personal data protection
pharmaceutical products 98–100, 102
Dawson, S.E. 115, 117–19, 121, 136
defamation 16, 258, 262
design see industrial design
developing countries 295
access to medicines 100–101, 103, 296
Directors Rights Collective of Canada (DRCC) 203
Douglas, T. 82
droit d’auteur 176

Educational Rights Collective of Canada (ERCC) 203–4, 206
Elgin, Lord 131
engravings 185–6
European Patent Office 71
European Union 295
geographical indications 38, 54, 62–5
Canada–European Community
Wine and Spirits Agreement 45, 50–53, 64–5, 66, 307
pharmaceutical products 99, 101
complaint to WTO 91–2
trademarks 32
evergreening practices 94–5

federal powers 3–4, 296–7, 309
copyright 4, 8, 11, 12, 113, 296
paramourcy, doctrine of 14
patents 4, 8, 11, 12, 113, 296
pharmaceutical products 82, 87
privacy 249

trademarks 3–6
s. 7 Trade-marks Act 6–13, 16–18, 20
s. 19 Trade-marks Act 14
Fischler, F. 64–5
Fleming, P.L. 110
Fox, H.G. 109, 115
France 36, 37, 39, 71, 88, 137
moral rights 177, 194
droit d’auteur 176

Gallichan, G. 110
Genetically Modified Organisms (GMOS) 69
see also lifeforms under patents
geographical indications (GIs)
Canada’s approach to protection of 37, 38, 39, 40, 45–6
certification marks 46, 53–7, 65
common law 45, 46, 57–61, 66
EU, agreement with 45, 50–53, 64–5, 66, 307
exceptions 49–50
wines and spirits 46–9
Canada’s stance on extension of 61–5
definition of 41
evolution of protection 38–41
passing off 36, 39, 45, 57–61, 66
Trade-marks Act 46–50, 53–4
TRIPS-level protection for 35–8, 41–2
exceptions 44–5
general protection 42–3
wines and spirits 43–4
wines and spirits 36, 37, 43–4, 46–50, 62, 66
EU 45, 50–53, 64–5, 66, 307
multilateral system of notification/registration 38, 44, 62
Germany 71–2, 88, 177, 183, 186
Gervais, D.J. 238
Gill, A.K. 12
goodwill
passing off 59
s. 22 Trade-marks Act 30–31
gorgonzola 37, 65
Goudreau, M. 18
harmonization
  bijuralism 14–15
  language, role of 19–21
  passing off 15–19, 20–21
Hasenzahl, C. 83
health care services 82, 84–5
  pharmaceutical products 82, 84–5, 87–8
human rights 309
  moral rights 177, 193
  privacy 245
  *Canadian Charter of Rights and Freedoms* 246, 247, 265
  *Québec Charter of Rights and Freedoms* 251–2
India 64, 71, 101
  indications of source 36, 39–40
  indigenous art 186
industrial design
  overlapping IP rights 267–70
  copyright 270–73
  normative principles 294
  patent 277–8
  trademark 282–3
industry, Minister of
  geographical indications 46–7
inheritance 195
injunctions
  interlocutory 93
injurious falsehood 7, 12, 16
Intellectual Property Office, Canadian (CIPO) 48
internalisation of foreign influences 296–7
  bijural nature of country 297–9
  comparative law, resort to 300–303
  see also civil law; common law
*International Convention for the Protection of New Varieties of Plants* 307
*International Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organisations* 307
*International Covenant on Civil and Political Rights* 245
*International Covenant on Economic, Social and Cultural Rights* 177, 193
international policy 306–9
Internet 226, 256, 304, 305
  collective licensing 220–21
  music 305
  CMOs and 202
  ISPs: legal challenge 230–37
  monitoring of sites 229
  Pharmacies 89
Italy 37, 50
Jamaica 57, 64
Jolliffe, R.S. 12
Keyes, A.A. 168, 178
Korea 101
Lamonde, Y. 110
languages, English and French 19–21, 178–9, 180, 182–3, 188, 189–90
Latin America 63
least-developed countries 101
Lewis, S. 100
libel 258
lifeforms see under patents
limitation periods
  geographical indications 42, 43, 49
  *Lisbon Agreement for the Protection of Appellations of Origin and Their International Registration* 40–42, 43
Mccarthy, J.T. 33
MacGillivray, E.J. 133–4
*Madrid Agreement for the Repression of False or Deceptive Indications of Sources of Goods* 40, 41
Manitoba 89, 248, 249–50
Marchi, Sergio 65
Menzies, Ted 52–3
Michaëlidès-Nouaros, Georges 174
Mignault, P.-B. 113, 115–17, 121, 164–5
Monsanto 77–8
moral rights 296, 298, 300
  1931 provision *Copyright Act*:
    s. 12(7) 170–71
    cases under 172–5
    criticism and use of 171–2
    consent and waiver 192–4
    copyright and 176, 239–40, 264
    defences, absence of express 191–2
Index

development prior to 1928
nineteenth century 164–5
twentieth century: case law 165–6
twentieth century: statute 167–8
1920s 168–70
distinctive Canadian features 175–80
indirect infringement, absence of 192
inheritance of 195
key elements 180–81
anonymity, right of 187, 191, 307
attribution/association, right of 187–91
integrity, right of 181–7
protection period 194
waiver and consent 192–4
MP3 player 305
Murray, J. 136
music performing rights 200–201

Nadeau, A. 18, 21
NAFTA (North American Free Trade Agreement) 45, 81, 86, 97, 98, 295, 307
national approaches, creation of 295–6, 303–4
administrative institutions
Copyright Board see Copyright Board of Canada
PMPRB 86–7, 88–90, 102–3, 305–6
internalisation of foreign influences 296–7
bijural character 297–9
comparative law 300–303
international policy 306–9
nationalism 301
neighbouring rights 201, 298, 300–301, 304, 307
Neighbouring Rights Collective of Canada (NRCC) 201, 207, 214
Neill, E. 254–5
New Brunswick 19
New Zealand 37
Newfoundland 249–50
Norway 101
oncomouse 68, 69, 74–7
Ontario 87, 248–9
Organisation for Economic Co-operation and Development (OECD) 87

Guidelines on the Protection of
Privacy and Transborder Flows of Personal Data 244, 257–8
overlapping IP rights 308
copyright – industrial design 270–73
copyright – patent 273–7
copyright – trademark 283–9
industrial design – trademark 282–3
normative principles 289–93
patent – industrial design 277–8
patent – trademark 279–82

paintings 185–6
Pakistan 64
paramountcy, doctrine of 14
Paris Convention for the Protection of Industrial Property 307
indications of source and appellations of origin 39–40, 41, 45
patents
compulsory licences 84
trademarks 22–3, 30, 34
Parker, G.L. 110, 126, 132
Parma ham 50, 65
passing off 5, 7, 15–19, 20–21, 36
functionality, doctrine of 279, 281–2
geographical indications 36, 39, 45, 57–61, 66
titles of literary works 284–6
Patented Medicine Prices Review Board (PMPRB) 86–7, 88–90, 102–3, 305–6
patents 298, 299
copyright and 158, 273–7
federal powers 4, 8, 11, 12, 113, 296
pharmaceutical products 82, 87
lifeforms
background 67–9
creation of transgenic animals/plants 69
hybridization techniques 73–4
legislation and case law 70–78
Plant Breeders’ Rights Act 76–7
recombinant DNA techniques 73–4
transgenic canola 69, 77–8
transgenic mouse/oncomouse 68, 69, 74–7
volunteer plants 78

Ysolde Gendreau - 9781848445024
Downloaded from Elgar Online at 12/30/2018 12:02:55AM
via free access
yeast culture 72–3
overlapping IP rights 267–70
copyright 273–7
industrial design 277–8
normative principles 294
trademark 279–82
pharmaceutical patent policy
access to medicines regime 100–101, 103, 296
compulsory licences 83–7
data protection 98–100, 102
drug price regulations 87–90
exceptions to rights conferred by patents 90–92
NOC Regulations 92–6, 102
PMPRB 86–7, 88–90, 102–3, 305–6
term of protection 96–8
WTO dispute settlement 91–2, 97–8
public inspection 253
Perrault, A. 115, 119–21
personal data protection confidentiality, role of 252–8
legislation 241–4, 246
PIPEDA 231, 241–2, 244, 258–64, 266
privacy 241, 244–52
public interest, private sector and 260–66
public sector and access to information 242–4, 265
revisiting BMG v. John Doe 258–60
Personal Information Protection and Electronic Documents Act (PIPEDA) 231, 241–2, 244, 258–64, 266
PhRMA 89
plants, transgenic see lifeforms under patents
Playwrights Union of Canada 204
precedent 20
privacy confidentiality, role of 252–8
criminal context 246, 248, 253, 264, 266
intellectual property rights 237–41
legislation 249–52
legitimate privacy concerns 241, 245–52
personal data protection 241–4, 246
PIPEDA 231, 241–2, 244, 258–64, 266
public interest 260–66
revisiting BMG v. John Doe 258–60
tort of invasion of 248–9
private sector personal data protection 241–2, 243, 266
Producers Audiovisual Collective of Canada 203
property rights copyright 237–41
overlapping see overlapping IP rights
provincial powers 296
business names, adoption of 13–14
health care services 82, 84–5
pharmaceutical products 82, 84–5, 87–8
paramountcy, doctrine of 14
pharmaceutical industry 82, 87–8
privacy 249
property and civil rights 5
trademarks 3–14, 21
public goods 216
public interest census 248
copyright 240–41
criminal process 248, 264
personal data protection and private sector 260–66
revisiting BMG v. John Doe 258–60
income tax 248
public sector access to government information 242–4, 265
personal data protection 242–4
Québec 15, 296
access to government information 242
Civil Code 45
art. 1457 15–16, 18, 19, 57–8
copyright 123–4
CMOs 202, 203, 204
harmonization
passing off 15–19, 20–21
language 19–21
personal data protection 241–2
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>pharmaceutical industry 82, 87–8</td>
</tr>
<tr>
<td>pharmaceutical products 87</td>
</tr>
<tr>
<td>privacy 251–2</td>
</tr>
<tr>
<td><em>Québec Charter of Rights and Freedoms</em> 251–2</td>
</tr>
<tr>
<td><strong>Regroupement des artistes en arts visuels du Québec</strong> (RAAV) 203</td>
</tr>
<tr>
<td>Reichman, J.H. 83</td>
</tr>
<tr>
<td>Richard, H.G. 17</td>
</tr>
<tr>
<td>Rioja 44</td>
</tr>
<tr>
<td>Royal Commission 282–3, 292</td>
</tr>
<tr>
<td>SACD (Société des auteurs et compositeurs dramatiques) 204</td>
</tr>
<tr>
<td>Saskatchewan 249–50</td>
</tr>
<tr>
<td>Scheppele, K. 254</td>
</tr>
<tr>
<td>Schmeiser, P. 77–8</td>
</tr>
<tr>
<td>Scotch 35</td>
</tr>
<tr>
<td>sculptures 185–6</td>
</tr>
<tr>
<td>services</td>
</tr>
<tr>
<td>certification marks 56</td>
</tr>
<tr>
<td>Seville, C. 109, 136</td>
</tr>
<tr>
<td>Sherman, B. 268</td>
</tr>
<tr>
<td>Shortt, J. 135</td>
</tr>
<tr>
<td>small to mid-size enterprises 5</td>
</tr>
<tr>
<td><em>Société civile des auteurs multimédia</em> (SCAM) 203</td>
</tr>
<tr>
<td><em>Société de droits d’auteur en arts visuels</em> (SODART) 203</td>
</tr>
<tr>
<td><em>Société de gestion collective des droits des producteurs de phonogrammes et vidéogrammes du Québec</em> (SOPROQ) 203</td>
</tr>
<tr>
<td><em>Société des auteurs et compositeurs dramatiques</em> (SACD) 204</td>
</tr>
<tr>
<td><em>Société québécoise de gestion collective des droits de reproduction</em> (COPIBEC) 202, 214</td>
</tr>
<tr>
<td><em>Société québécoise des auteurs dramatiques</em> (SOQAD) 204</td>
</tr>
<tr>
<td>Society of Composers, Authors and Music Publishers of Canada (SOCAN) 200, 206, 207, 213, 214, 236</td>
</tr>
<tr>
<td>South Africa 295</td>
</tr>
<tr>
<td>Spain 36, 44, 88</td>
</tr>
<tr>
<td>Strömholm, S. 175</td>
</tr>
<tr>
<td><em>substitution</em> 5, 16</td>
</tr>
<tr>
<td>Switzerland 36</td>
</tr>
<tr>
<td>tax legislation 248</td>
</tr>
<tr>
<td>Tequila 35</td>
</tr>
<tr>
<td>trade secrets 12, 100, 253–4</td>
</tr>
<tr>
<td>trademarks 297</td>
</tr>
<tr>
<td>business names and 5, 13–14</td>
</tr>
<tr>
<td>certification marks 36, 46, 53–7, 65</td>
</tr>
<tr>
<td>confusion, concept of 23–7, 32, 34</td>
</tr>
<tr>
<td>international obligations 22–3</td>
</tr>
<tr>
<td>depreciation or dilution 27–34</td>
</tr>
<tr>
<td>international obligations 22–3, 27, 29–30, 34</td>
</tr>
<tr>
<td>famous or well known 22</td>
</tr>
<tr>
<td>confusion 23–7, 32, 34</td>
</tr>
<tr>
<td>depreciation or dilution 27–34</td>
</tr>
<tr>
<td>international obligations 22–3, 27, 29–30, 34</td>
</tr>
<tr>
<td>functionality, doctrine of 280–82</td>
</tr>
<tr>
<td>geographical indications and 42–4, 45, 46, 48–9, 50</td>
</tr>
<tr>
<td>certification marks 36, 46, 53–7, 65</td>
</tr>
<tr>
<td>wines and spirits 46–50, 66</td>
</tr>
<tr>
<td>overlapping IP rights 267–70, 308</td>
</tr>
<tr>
<td>copyright 283–9</td>
</tr>
<tr>
<td>industrial design 282–3</td>
</tr>
<tr>
<td>normative principles 294</td>
</tr>
<tr>
<td>patent 279–82</td>
</tr>
<tr>
<td>registered vs unregistered 4–13, 20, 21</td>
</tr>
<tr>
<td><em>Trade-marks Act</em> 6–14, 16–18, 20–21, 23–34</td>
</tr>
<tr>
<td>transgenic plants/animals see lifeforms under patents</td>
</tr>
<tr>
<td><em>TRIPS Agreement</em> 301, 306, 307</td>
</tr>
<tr>
<td>confidential information 254</td>
</tr>
<tr>
<td>GIs see geographical indications</td>
</tr>
<tr>
<td>patents 70–71, 86, 97, 100</td>
</tr>
<tr>
<td>trademarks 22–3, 27, 29–30, 34</td>
</tr>
<tr>
<td>Twain, M. 128, 284</td>
</tr>
<tr>
<td>unfair competition 21, 297, 302</td>
</tr>
<tr>
<td>art. 1457 <em>Civil Code of Québec</em> 15–16, 18, 19</td>
</tr>
<tr>
<td>federal powers 12</td>
</tr>
<tr>
<td>geographical indications 36, 39</td>
</tr>
<tr>
<td>Index</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Paris Convention 39–40</td>
</tr>
<tr>
<td>TRIPS Agreement 42</td>
</tr>
<tr>
<td>United Kingdom</td>
</tr>
<tr>
<td>copyright</td>
</tr>
<tr>
<td>case law 143–54, 161, 273</td>
</tr>
<tr>
<td>collective management 207, 215</td>
</tr>
<tr>
<td>tribunal 207</td>
</tr>
<tr>
<td>geographical indications 57</td>
</tr>
<tr>
<td>intellectual property history 268–9</td>
</tr>
<tr>
<td>moral rights 163, 175, 195</td>
</tr>
<tr>
<td>attribution, right of 187</td>
</tr>
<tr>
<td>copyright and 176</td>
</tr>
<tr>
<td>false attribution 190–91</td>
</tr>
<tr>
<td>indirect infringement 192</td>
</tr>
<tr>
<td>integrity, right of 174, 181, 183, 184, 186</td>
</tr>
<tr>
<td>legislation 179, 180</td>
</tr>
<tr>
<td>waiver 193</td>
</tr>
<tr>
<td>trademarks 28, 32–3</td>
</tr>
<tr>
<td>United States 299</td>
</tr>
<tr>
<td>book publishers</td>
</tr>
<tr>
<td>exports to Canada 108, 126–34, 135</td>
</tr>
<tr>
<td>Canadian economy and 81, 85</td>
</tr>
<tr>
<td>copyright 221</td>
</tr>
<tr>
<td>music industry 228</td>
</tr>
<tr>
<td>originality 142</td>
</tr>
<tr>
<td>geographical indications 36, 37, 61, 65</td>
</tr>
<tr>
<td>certification marks 54</td>
</tr>
<tr>
<td>Madrid Agreement 40</td>
</tr>
<tr>
<td>Uruguay Round 54</td>
</tr>
<tr>
<td>Internet Pharmacies 89</td>
</tr>
<tr>
<td>moral rights 175, 177, 179, 195, 196</td>
</tr>
<tr>
<td>attribution, right of 187</td>
</tr>
<tr>
<td>category of works, narrow 176</td>
</tr>
<tr>
<td>indirect infringement 192</td>
</tr>
<tr>
<td>integrity right, equivalents of 183, 184, 186</td>
</tr>
<tr>
<td>protection period 194</td>
</tr>
<tr>
<td>waiver 193</td>
</tr>
<tr>
<td>trademarks 28, 30, 32, 33–4, 297</td>
</tr>
<tr>
<td>Universal Declaration of Human Rights</td>
</tr>
<tr>
<td>177, 193, 245</td>
</tr>
<tr>
<td>Vaver, D. 149, 185, 293</td>
</tr>
<tr>
<td>Westin, A.F. 246–7</td>
</tr>
<tr>
<td>WIPO treaties 306</td>
</tr>
<tr>
<td>World Trade Organization (WTO) 36</td>
</tr>
<tr>
<td>Agreement on Trade-Related Aspects of Intellectual Property Rights</td>
</tr>
<tr>
<td>see TRIPS Agreement</td>
</tr>
<tr>
<td>lifeform patents 79</td>
</tr>
<tr>
<td>pharmaceutical products</td>
</tr>
<tr>
<td>2003 decision 100, 103</td>
</tr>
<tr>
<td>Panel: EU complaint 91–2</td>
</tr>
<tr>
<td>Panel and Appellate body: US complaint 97–8</td>
</tr>
</tbody>
</table>